Choice Equity Broking's report on Lupin
We continue to believe LPC will sustain its strong growth trajectory, led by high-value launches in North America and India. The company has demonstrated strong execution in scaling up new products, such as Tolvaptan, Mirabegron, Albuterol and gSpiriva, reinforcing confidence in its differentiated pipeline. Management has revised EBITDA margin guidance upwards to 25–26% (from 24–25%) for FY26E, supported by a lower mix of in-licensed products in India. While margin may contract ~100bps in FY27E due to planned higher R&D spend, we expect normalisation as newer complex launches ramp up.
Outlook
We forecast revenue/EBITDA/PAT to grow at a CAGR of 12%/15%/12% over FY25–28E and continue to value the stock at 25x the average of FY27–28E EPS, arriving at an unchanged TP of INR 2,375. We maintain our BUY rating.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
